Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.48 |
| ▸ | SCN4A | P35499 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1486184 | 1.00 | HSD17B10 (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL190042 | 1.00 | HSD17B10 (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| Hydrochloric Acid SCHEMBL29889454 | 0.98 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL2737884 | 0.95 | FKBP1A (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL2898129 | 0.95 | FKBP1A (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL88684 | 0.95 | FKBP1A (0.58) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL6272597 | 0.94 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL3467497 | 0.94 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL6361642 | 0.94 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA | |
| SCHEMBL18455416 | 0.94 | FKBP1A (0.57) | HSD17B10SMN1; SMN2NPC1FKBP1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119505138-A | Chiral covalent organic framework mimic enzyme catalyst and preparation method and application thereof | 浙江工业大学 | 2025-02-25 | — | — | CN | claimed |
| CN-112121853-B | Mesoporous hollow silica nanosphere loaded with prolinol catalyst as well as preparation method and application of mesoporous hollow silica nanosphere | 重庆邮电大学 | 2023-03-28 | — | — | CN | claimed |
| CN-111057736-B | Application of lipase in splitting BOC-DL-proline methyl ester | 浙江工业大学 | 2022-03-18 | — | — | CN | claimed |
| CN-102166530-B | Bi-chiral organic small molecular catalyst and preparation method thereof | UNIV SHANGHAI | 2013-03-06 | — | — | CN | claimed |
| CN-102166530-A | Bi-chiral organic small molecular catalyst and preparation method thereof | UNIV SHANGHAI | 2011-08-31 | — | — | CN | claimed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122036924-A | Synthetic method of bionic collagen hexapeptide | 成都欣肽生物科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-5242903-A | Enzyme inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 1993-09-07 | — | — | US | disclosed |
| US-5095006-A | Enzyme inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-10 | — | — | US | disclosed |
| EP-0412350-A2 | Renininhibitors, procedure for their preparation and use as medicaments | BAYER AG (DE) | 1991-02-13 | — | — | EP | disclosed |
| EP-0324993-A1 | Sparsomicin (Sc-Rs) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (Sc-Rs) compounds | Stichting Katholieke Universiteit (NL) | 1989-07-26 | — | — | EP | disclosed |
| US-4837349-A | Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same | SUNTORY LIMITED (JP) | 1989-06-06 | — | — | US | disclosed |
| US-4820712-A | Sparsomycin (SC-RS) compounds having antitumor activity, a process for their preparation and pharmaceutical compositions containing sparsomycin (SC-RS) compounds | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 1989-04-11 | — | — | US | disclosed |
| EP-0217243-A2 | Tertiary-butyldimethylsilyl carbamate derivative and process for producing the same | SUNTORY LIMITED (JP) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | HSD17B10 1079/4885SMN1; SMN2 1998/4885NPC1 2732/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | HSD17B10 3641/4885SMN1; SMN2 2048/4885NPC1 1662/4885 |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | HSD17B10 1667/4885SMN1; SMN2 2057/4885NPC1 707/4885 |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | GLP1R, GIPR, GPR119 | HSD17B10 1667/4885SMN1; SMN2 2057/4885NPC1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.